---
title: "Rani Therapeutics Holdings (RANI) news: Nasdaq notice"
url: "https://aibio.space/companies/rani-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "RANI Nasdaq notice news: Rani Therapeutics gets Nasdaq notice over $1.00 minimum bid price. Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), United States."
---

RANI Rani Therapeutics Holdings, Inc. NASDAQ · United States

# Rani Therapeutics Holdings (RANI) news RANI Nasdaq notice news

Listings · 2026-05-15

## [Rani Therapeutics gets Nasdaq minimum bid price notice, CFO Svai Sanford to resign](https://aibio.space/news/rani-therapeutics-gets-nasdaq-minimum-bid-price-notice-cfo-svai/)

Rani Therapeutics (Nasdaq: RANI) has until November 9, 2026, to regain bid price compliance. It also reported cash, cash equivalents and marketable securities of $43.4 million and a first quarter net loss of $8.0 million.

## Latest Rani Therapeutics Holdings news

1. 2025-07-11 Financings [Rani Therapeutics registers resale of 13,160,172 Series D warrant shares](https://aibio.space/news/rani-therapeutics-registers-resale-13-160-172-series-d-warrant-shares/) Rani Therapeutics filed a resale prospectus on July 11, 2025 covering up to 13,160,172 Class A shares issuable on exercise of a Series D warrant. The company says it will receive no proceeds from the resale itself.
2. 2025-06-26 Listings [Rani Therapeutics gets Nasdaq notice over $1.00 minimum bid price](https://aibio.space/news/rani-therapeutics-gets-nasdaq-notice-1-00-minimum-bid-price/) Rani Therapeutics received a Nasdaq notice on June 20, 2025 that its Class A shares had a closing bid price below $1.00 for 30 consecutive business days. Its deadline to regain compliance is December 17, 2025, and the notice gives no closing price.
3. 2025-05-20 Financings [Rani Therapeutics cuts warrant exercise price to $0.65 for about $4.3 million in gross proceeds](https://aibio.space/news/rani-therapeutics-cuts-warrant-exercise-price-0-65-about-4-3-million/) Rani Therapeutics cut the exercise price of two outstanding warrants from $3.08 and $3.00 to $0.65 so an existing institutional investor would exercise them, for gross proceeds of about $4.3 million before advisory fees. The investor also receives a new Series D warrant for up to 13,160,172 shares.

## Rani Therapeutics Holdings at a glance

- **Ticker**: RANI

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $4.9 million

### Related companies

- [OS Therapies](https://aibio.space/companies/os-therapies/) AMEX: OSTX
- [ImageneBio](https://aibio.space/companies/imagenebio/) NASDAQ: IMA
- [Faeth Therapeutics](https://aibio.space/companies/faeth-therapeutics/) NASDAQ: FTH
- [Xencor](https://aibio.space/companies/xencor/) NASDAQ: XNCR
- [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) OTC: SQZB
- [OPTIGENEX INC](https://aibio.space/companies/optigenex/) OTC: OPGX
- [Cue Biopharma](https://aibio.space/companies/cue-biopharma/) NASDAQ: CUE
- [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO

### Also on NASDAQ

- [Heartflow](https://aibio.space/companies/heartflow/) HTFL
- [SERA PROGNOSTICS, INC.](https://aibio.space/companies/sera-prognostics/) SERA
- [Eocene](https://aibio.space/companies/eocene/) EOCN
- [NextCure](https://aibio.space/companies/nextcure/) NXTC
- [Neuronetics](https://aibio.space/companies/neuronetics/) STIM
- [Pulmonx](https://aibio.space/companies/pulmonx/) LUNG

## What Rani Therapeutics Holdings does

Rani Therapeutics is a clinical-stage biotherapeutics company developing technology to deliver biologics and drugs orally, as an alternative to injections. Its drug-agnostic platform centers on the RaniPill capsule, which is designed to deliver antibodies, proteins, peptides and oligonucleotides. There are two configurations. The RaniPill GO is designed to deliver up to a 3 mg dose in microtablet form, and the RaniPill HC is a high-capacity version intended for liquid payloads up to 200µL. The company says it has completed three Phase 1 clinical trials with the RaniPill GO. In December 2025 it initiated a Phase 1 trial of RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist for obesity. The company does not have any products approved for sale and has not generated product revenue. It is pursuing partnerships to apply its oral delivery technology to third-party biologics and drugs. In October 2025 it entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd.

| Product or program | What it is | Stage |
|---|---|---|
| RaniPill GO | Oral capsule designed to deliver up to a 3 mg dose in microtablet form | three Phase 1 clinical trials completed |
| RaniPill HC | High-capacity oral capsule for liquid payloads up to 200µL | tested preclinically; in development |
| RT-114 | RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102) for obesity | Phase 1 initiated in December 2025 |

Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/rani-20251231.htm).

## Rani Therapeutics Holdings annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$1.6 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) |
| Research and development | [$20.2 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) | [$26.7 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) |
| Net income (loss) | [-$29.7 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) | [-$30.0 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) |
| Cash from operations | [-$18.7 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) | [-$35.5 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) |
| Cash and equivalents | [$18.6 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349245/) | [$3.8 million](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Rani Therapeutics Holdings

Has Rani Therapeutics Holdings received a Nasdaq deficiency notice?

Our latest story on this, dated Jun 26, 2025: "Rani Therapeutics gets Nasdaq notice over $1.00 minimum bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rani-therapeutics-gets-nasdaq-notice-1-00-minimum-bid-price/).

What is the ticker symbol of Rani Therapeutics Holdings?

Rani Therapeutics Holdings, Inc. trades under the ticker RANI on NASDAQ.

Where is Rani Therapeutics Holdings listed?

Rani Therapeutics Holdings, Inc. is listed on NASDAQ.

What is the SEC CIK of Rani Therapeutics Holdings?

The SEC Central Index Key (CIK) for Rani Therapeutics Holdings, Inc. is 1856725. Its filings are on SEC EDGAR.

Which country or territory is Rani Therapeutics Holdings listed under?

Our directory records Rani Therapeutics Holdings, Inc. under United States.

What does Rani Therapeutics Holdings do?

Our directory classifies Rani Therapeutics Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Rani Therapeutics Holdings?

The ISIN recorded for Rani Therapeutics Holdings, Inc. is US7530181004.

Does aibio.space cover Rani Therapeutics Holdings?

aibio.space lists Rani Therapeutics Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Rani Therapeutics Holdings incorporated?

SEC records list its state or country of incorporation as CA.

What does Rani Therapeutics Holdings develop?

Rani Therapeutics is a clinical-stage biotherapeutics company developing technology to deliver biologics and drugs orally, as an alternative to injections. Its drug-agnostic platform centers on the RaniPill capsule, which is designed to deliver antibodies, proteins, peptides and oligonucleotides.

What is RaniPill GO from Rani Therapeutics Holdings?

RaniPill GO: Oral capsule designed to deliver up to a 3 mg dose in microtablet form Stage: three Phase 1 clinical trials completed.

What is RaniPill HC from Rani Therapeutics Holdings?

RaniPill HC: High-capacity oral capsule for liquid payloads up to 200µL Stage: tested preclinically; in development.

What was Rani Therapeutics Holdings's revenue last year?

$1.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Rani Therapeutics Holdings profitable?

Rani Therapeutics Holdings, Inc. reported a net loss of $29.7 million for the fiscal year ended Dec 31, 2025, and used $18.7 million of cash in operations, per its annual report to the SEC.

How much does Rani Therapeutics Holdings spend on research and development?

$20.2 million in the fiscal year ended Dec 31, 2025, per its annual report.

## Investor discussion: Rani Therapeutics Holdings

Members talk about Rani Therapeutics Holdings (RANI). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Rani Therapeutics Holdings, newest first. Each line links the filing it comes from.

1. 2026-05-27 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1856725/000119312526239968/d113796d424b5.htm)
2. 2026-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/rani-ex99_1.htm)
3. 2026-01-02 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,3.03,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/d848686d8k.htm)
4. 2025-12-03 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1856725/000119312525306829/d833820d424b5.htm)
5. 2025-10-17 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1856725/000119312525241963/d38236d8k.htm)
6. 2025-07-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1856725/000119312525158214/d27241d424b5.htm)
7. 2025-06-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1856725/000095017025090384/rani-20250620.htm)
8. 2025-05-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1856725/000119312525121895/d34812d424b5.htm)
9. 2025-05-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1856725/000095017025064624/rani-20250501.htm)
10. 2025-04-09 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1856725/000095017025052527/rani-20250407.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RANI on TradingView](https://www.tradingview.com/symbols/NASDAQ-RANI/).

## SEC filings and registration

- **SEC name**: Rani Therapeutics Holdings, Inc.

- **CIK**: 1856725

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: RANI (Nasdaq)

- **State or country of incorporation**: CA

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 2051 RINGWOOD AVENUE, SAN JOSE, CA, 95131

- **Phone**: (408) 457-3700

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349245/rani-20260630.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-20260813.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1856725/000119312526331594/d177572d8k.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/rani-20260624.htm) filed 2026-06-30
- [8-K](https://www.sec.gov/Archives/edgar/data/1856725/000119312526245636/rani-20260528.htm) filed 2026-05-29
- [8-K](https://www.sec.gov/Archives/edgar/data/1856725/000119312526239977/d312913d8k.htm) filed 2026-05-27
- [424B5](https://www.sec.gov/Archives/edgar/data/1856725/000119312526239968/d113796d424b5.htm) filed 2026-05-27
- [10-Q](https://www.sec.gov/Archives/edgar/data/1856725/000119312526226703/rani-20260331.htm) filed 2026-05-15

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001856725), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Rani Therapeutics Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RANI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Rani Therapeutics Holdings, Inc.

- **Ticker**: RANI

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US7530181004

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RANI/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/rani-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rani Therapeutics Holdings (RANI) news: Nasdaq notice", 2026-10-31, https://aibio.space/companies/rani-therapeutics/